Dr. Vance Fowler

Dr. Fowler has extensive expertise in clinical and translational research in bacterial infections that has led to 20 years (1999-2019) of continuous NIH funding as PI. He is currently PI on a K24, a competitively renewed R01, a $20 million award from NIAID for a multinational randomized trial of patients with staphylococcal bacteremia (DMID protocol 09-0080) and is the Contact PI of the Antibacterial Resistance Leadership Group, a grant totaling $62 million to design, prioritize, and execute clinical research in antibacterial resistance. Dr. Fowler’s additional research accomplishments include: 1) creation of the S. aureus Bacteremia Group (SABG). Created by Dr. Fowler while he was still a 1st year Medicine Resident, the SABG has continuously enrolled patients at Duke with MDR infections since 1994. As a result, SABG now contains one of the world’s largest prospective biorepositories of bloodstream isolates, patient serum and DNA, and outcomes data on patients with S. aureus bacteremia (n>2000) and Gram-negative bacteremia (n>1500). Discoveries from this resource have revolutionized our management of patients with S. aureus bacteremia. 2) Co-founder of the International Collaboration on Endocarditis, a prospective cohort of >5000 patients with endocarditis from 60 centers in >25 countries that has now resulted in >35 peer-reviewed publications and revolutionized our understanding of the disease. From this resource, Dr. Fowler published the critical observation in the JAMA that S. aureus is now the leading cause of endocarditis in the industrialized world. 3) Lead author on the landmark registrational multinational trial evaluating daptomycin for the treatment of S. aureus bacteremia, published in the New England Journal of Medicine. Data from this study ultimately led to the FDA indication of daptomycin for S. aureus bacteremia and right-sided endocarditis. 4) Lead author on the recent multinational randomized double blind placebo controlled trial of Merck V710 vaccine for S. aureus, published in the JAMA in 2013. He has over 150 peer-reviewed original publications in his area of expertise, and has received numerous awards for research excellence including Young Investigator awards from the American Federation for Medical Research (AFMR) and American Society for Microbiology (both 2001); the Williams award for the top clinical researcher less than 45 years of age at Duke University School of Medicine (2006); Infectious Diseases Society of America (IDSA)/SHEA Special Recognition Award in MRSA (2007); the IDSA Oswald Avery Award (2008); the AFMR Outstanding Investigator Award (2011); and election into American Society for Clinical Investigation (2007) and Association of American Physicians (2013). In 2012, he received the Clinical Research Achievement Award from the Clinical Research Forum, for publishing one of the top ten clinical research papers in the United States.

CONFERENCE QUERIES

ISCVID 2017 Conference Account Manager for all conference logistics, programme, sponsorship and exhibition queries:

Tadhg Moriarty
Conference Partners Ltd
T:+353 (0)1 296 8688
E: Conference Organisers

CONFERENCE PROGRAMME

If you require information on the Conference Programme please email your query to:

CONFERENCE ACCOMMODATION

If you require registration, accommodation assistance please contact a member of the ISCVID 2017 delegate services team:

T: +353 (0)1 296 8688
E: Conference Organisers

SPONSORSHIP & EXHIBITION

To enquire about sponsorship and exhibition packages please contact:

Conference Partners Ltd
T: +353 (0)1 2968688
E: Conference Organisers